Leading Biotech & Healthcare Hedge Funds manage nearly $100 Billion; Gainers accumulate $5.2 Billion
|February 2nd, 2015||
|The most recent rankings for the Top 75 Healthcare, Pharma and Biotech Focused Hedge Fund list reveal that the top funds now manage $98.5 billion in U.S. equity assets. |
43% of the hedge funds on the list saw their assets increase over the third quarter, adding $5.2 billion in assets under management. Leading the top gainers were Glenview Capital Management, Pershing Square Capital Management and OrbiMed Advisors
Glenview Capital’s asset gains enabled Larry Robbins’ hedge fund to reclaim the top spot on the the Top Healthcare, Pharma and Biotech Hedge Fund List from Andreas Halvorsen’s Viking Global. Greenwich-based Viking Global fell off the list, after having trimmed its healthcare sector allocation to just 24%.
Ranking Methodology: The Top Healthcare, Pharmaceutical and Biotechnology Hedge Fund rankings, along with their Key Decision Makers, are compiled on a quarterly basis using hedge fund firms’ overall U.S. equity assets under management. The list includes the top hedge funds that have more than 35% of their U.S. equity assets invested in U.S. listed Healthcare, Pharma & Biotech companies. To view the Top Healthcare, Pharma & Biotech Hedge Fund list in its entirety, please visit HedgeTracker’s Hedge Fund Portal.
For Detailed Investor Profiles on these Investors, click below: